SCHEMBL4713709

SCHEMBL4713709

CC(=O)OCc1cccc(C#Cc2cccc(C)n2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.66
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
CYP2C19 P33261 1/20 0.51
THPO P40225 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRM1 Q13255 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715336 0.91 GRM5 (0.54) GRM5KDM4EMEN1NPC1ALDH1A1
SCHEMBL3346401 0.80 ALDH1A1 (0.50) GRM5ALDH1A1CYP3A4
SCHEMBL4713609 0.80 GRM5 (0.65) GRM5KDM4EMEN1NPC1ALDH1A1
SCHEMBL3346985 0.78 GRM5 (0.42) GRM5ALDH1A1CYP3A4
SCHEMBL4710798 0.76 GRM5 (0.54) GRM5KDM4EMEN1NPC1ALDH1A1
SCHEMBL4710493 0.76 GRM5 (0.60) GRM5KDM4EMEN1NPC1ALDH1A1
SCHEMBL4712241 0.75 GRM5 (0.67) GRM5KDM4EMEN1NPC1ALDH1A1
SCHEMBL2659356 0.74 ALDH1A1 (0.56) ALDH1A1CYP3A4
SCHEMBL4773202 0.74 ALDH1A1 (0.56) ALDH1A1CYP3A4
SCHEMBL4710450 0.73 GRM5 (0.58) GRM5KDM4EMEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed